NDAOPHTHALMICDRUG-ELUTING CONTACT LENS
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
4
Data completeness
5/8 — Partial
ACUVUE THERAVISION WITH KETOTIFEN (ketotifen fumarate) by Johnson & Johnson is state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake). Approved for allergic conjunctivitis, vernal keratoconjunctivitis, seasonal allergic conjunctivitis. First approved in 2022.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACUVUE THERAVISION WITH KETOTIFEN is a drug-eluting contact lens combining optical correction with ketotifen fumarate, a mast cell stabilizer and H1 receptor antagonist. It treats allergic conjunctivitis, vernal keratoconjunctivitis, and seasonal allergic conjunctivitis by preventing eosinophil accumulation and blocking allergic itch for up to 12 hours while maintaining continuous lens wear. The product represents a novel modality that integrates therapeutics directly into the contact lens substrate.
Peak4.1 years to LOE
Product is at peak commercial stage with high competitive pressure (8/10), suggesting robust marketing and sales infrastructure supporting established team size and promotion budgets.
Mechanism of Action
state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake). Drug Component Ketotifen fumarate, a benzocycloheptathiophene derivative, is a H 1 receptor…
Indications (3)
Worked on ACUVUE THERAVISION WITH KETOTIFEN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.